Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8519MR)

This product GTTS-WQ8519MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8519MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2582MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ13848MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ15959MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ7603MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ14692MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ5079MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ14087MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ6251MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW